CD274 and small cell lung carcinoma: Aside from nivolumab and pembrolizumab, many other PD-1 and PD-L1 modulators have been developed and have shown activity in small cell lung cancer (SCLC), cutaneous squamous cell carcinoma, bladder cancer, and TNBC (35–42).